Robert Mcquade

Biography

As Executive Vice President & Chief Strategic Officer at Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) I am responsible for coordinating the development strategy for our compounds across their life cycle.   I have more than 30 years of experience in the discovery, development, and marketing of drugs for the treatment of mental illness.My career started as a post-doctoral fellow in central nervous system (CNS) research at Schering-Plough Pharmaceuticals and gradually advanced to Associate Director of CNS Pharmacology.  In this role, I supervised the biochemical pharmacology group in their efforts to discover new drugs for mental illness, including schizophrenia and Alzheimer’s disease.I next joined the Global Medical Affairs team at Bristol-Myers Squibb (BMS). While at BMS, I was responsible for various products, including psychiatric treatments for generalized anxiety disorder and major depressive disorder.  More importantly, I was part of the team that helped form the alliance between BMS and Otsuka for the development and commercialization of aripiprazole.It was only natural that I ultimately joined Otsuka in 2004 to oversee global medical affairs for ABILIFY® (aripiprazole).  My roles have grown over the years and now I am responsible for the global development strategy for Otsuka’s compounds in the CNS, cardio-renal and oncology therapeutic areas. In addition, I am involved in many of Otsuka’s external collaborations and business development initiatives.

Research Interest

Business Development